Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Awareness: Key To Preventing Theft And Diversion Of Products
Security experts from the FBI, DHS and the private sector emphasized believe that importance of awareness in preventing the theft and diversion of chemicals is inevitable. According to
Security experts from the FBI, DHS and the private sector emphasized believe that importance of awareness in preventing the theft and diversion of chemicals is inevitable. According to
Staff from the US Senate Homeland Security and Governmental Affairs Committee warned summit attendees that legislation to make permanent chemical site security rules was unlikely to pass this
ICON has acquired Veeda Laboratories, a wholly-owned subsidiary of Veeda Clinical Research Group. The acquisition adds to ICON Development Solutions’ existing bioanalytical and immunoassay capabilities, which are delivered
The World Health Organization (WHO) has awarded prequalification to Cervarix, GlaxoSmithKline’ (GSK) cervical cancer vaccine. GSK filed Cervarix for WHO prequalification in September 2007, less than one week
Spectrum Pharmaceuticals has submitted a formal response to the Complete Response Letter it received from the FDA. It was regarding its supplemental Biologics License Application (sBLA) for ZEVALIN
Rigel has announced that R788 (fostamatinib disodium) produced significant clinical improvement in rheumatoid arthritis (RA) patients. The results were obtained from the recently completed TASKi2 phase 2b clinical
Amarin has reached an agreement with the FDA under a Special Protocol Assessment (SPA), for its planned phase-III clinical trial of AMR101 (ethyl-EPA) in patients with mixed dyslipidemia.
Dow Basic Plastics Licensing and Catalyst (Dow) has increased the capacity at its SHAC Catalyst plant in Norco by 20%. The SHAC Catalysts are used in the production
Life Sciences Research (LSR) has entered into a merger agreement to be acquired by Lion Holdings, for $8.50 per share in cash. Under the terms of the agreement,
Merck & Co. and Portola Pharmaceuticals have signed a global collaboration and license agreement for the development and commercialization of betrixaban. Its an investigational oral Factor Xa inhibitor